Clinical Trials

Syntara are global leaders in amine oxidase chemistry and biology with more than a decade of experience in this field. This has resulted in extensive collaborations with scientific and clinical thought leaders worldwide and multiple publications in high impact scientific journals.

Syntara’s drug pipeline includes drugs at discovery, pre clinical, clinical phase 1 and phase 2 stage. Syntara has active clinical programs in three therapeutic areas:

null

Cancer

null

Skin scarring

null

Neurodegenerative disease

The table below summarises the active and planned clinical trials the company targets delivering data from in the next two years.
Drug Candidate Indication Phase Trial design Status Upcoming Milestones Addressable market (US$)
SNT-5505
 Myelofibrosis (MF) Phase 2
  • Open label 12 month study (n=15)
  • MF patients receiving a stable dose of ruxolitinib (JAK inhibitor)

First patient

Q4 2023

 2H 2024: Interim 6 month data ~$1 billion
Myelodysplastic Syndrome (MDS) Phase 1c/2
  • Dose escalation/6 month expansion (n=30)
  • Transfusion dependent low/intermediate risk MDS patients

 

First patient

H2 2024

 Data H1 2025 ~$3.2 billion
Oral and Topical
Pan-LOX inhibitors
 Scar prevention Phase 1c
  • 6 month placebo controlled trial
  • Independent investigator trial
  • Patients with scarring subsequent to burn injury (n=60)

First patient

Q4 2023

 H1 2025 ~$3.5 billion
Modification of established scars Phase 1
  • Plan to initiate Phase 1/2 trial
  • Independent investigator trial
  • Patients with keloid or hypertrophic scars
  • Protocol under development
 TBD TBD ~$3.5 billion
SNT-4728
 IRDB and Parkinson’s Disease Phase 2
  • Double blind, placebo controlled
  • Patients with Isolated REM sleep behaviours disorder IRBD (n=40)
  • Majority funded by Parkinson’s UK
 Recruiting H1 2025 ~$3.5 billion

Syntara

Collaborating with scientific and clinical thought leaders worldwide and multiple publications in high-impact scientific journals.